source
- FDA releases proposed commitment letter detailing changes to GDUFA IV programThe U.S. Food and Drug Administration has issued a proposed commitment letter for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA IV). The letter follows several months o…
- Epicrispr raises $90 million to push epigenetic editing drug EPI-321 for rare muscle disorder FSHDEpicrispr Biotechnologies announced a $90 million Series C financing to accelerate development of its epigenetic editing therapy EPI-321 for facioscapulohumeral muscular dystrophy (FSHD), a rare ge…